parkinson's disease triple agonist glp-1 gip glucagon clinical trial Glucagon-like peptide-1 (GLP-1) The clinically most relevant mechanisms

other outcomes were cardiovascular and total death, nonfatal myocardial infarction (MI), nonfatal stroke, hospitalization for heart failure (HHF), and renal outcome

Is allulose a GLP-1 agonist

Understand about the investigational Alluvi Retatrutide 40 mg injection a GLP-1 + GIP + Glucagon triple-agonist studied for obesity

Understanding GLP-1 and Its Role in the Body GLP-1 is a hormone naturally produced in the gut

Due to the bodys natural tendency to restore its former weight, many people regain their lost weight when they stop using GLP-1 drugs.

Purpose of Review This review explores the role of GLP-1 receptor agonists (GLP-1 RAs) in addressing metabolic dysfunction and neurodegeneration in Parkinsons disease (PD), focusing on body weight regulation and neuroprotection